Lausanne, Vaud, Switzerland In 2003 was created VINCI CAPITAL, which is appeared as VC. The fund was located in Europe if to be more exact in Switzerland. The main office of represented VC is situated in the Lausanne.
We also calculated 6 valuable employees in our database.
Among the most popular fund investment industries, there are Software, Food and Beverage. For fund there is a match between the location of its establishment and the land of its numerous investments - Switzerland. The fund has exact preference in some founders of portfolio startups. In case when startup counts 3 or 5+ of the founder, the chance for it to get the investment is meager. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Addex Therapeutics, Anergis, Beqom
The common things for fund are deals in the range of 10 - 50 millions dollars. The top amount of exits for fund were in 2019. The fund is constantly included in less than 2 investment rounds annually. This VINCI CAPITAL works on 11 percentage points more the average amount of lead investments comparing to the other organizations. The top activity for fund was in 2009. Speaking about the real fund results, this VC is 7 percentage points more often commits exit comparing to other organizations.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the VINCI CAPITAL, startups are often financed by Novartis Venture Fund, Dansk Innovation, BioMedPartners. The meaningful sponsors for the fund in investment in the same round are Wellington Partners, Swisscom Ventures, BioMedPartners. In the next rounds fund is usually obtained by Wellington Partners, Swisscom Ventures, Renaissance PME Foundation.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Bajaj Auto Finance | India, Maharashtra, Pune |
| BridgeWest | England, London, United Kingdom |
| Corning Technology Ventures | Boston, Massachusetts, United States |
| Day One Entrepreneurs & Partners | France, Ile-de-France, Paris |
| Dazhong Ziben | China, Shanghai |
| GSR | China, Hong Kong, Hong Kong Island |
| Hartree Partners | New York, New York, United States |
| Hnap | - |
| HSBC Bank | Illinois, Lake Forest, United States |
| InNEVenture Fund | - |
| Legend Ventures | Bethesda, Maryland, United States |
| Lianchuang Donglin | Chengdu, China, Sichuan |
| Maizijinfu | China, Shanghai |
| Next Wave Impact | Colorado, Denver, United States |
| Ningbo Meishan Baoshui Gangqu Tongli Zhicheng Touzi | China, Ningbo Shi, Zhejiang |
| Osage Venture Partners | Bala Cynwyd, Pennsylvania, United States |
| ReliaStar Financial Corp | Minneapolis, Minnesota, United States |
| Seven-Eleven Japan | Japan, Tokyo |
| Vanho Securities | China, Guangdong, Shenzhen |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Anergis | $8M | 07 Feb 2014 | Vaud, Switzerland | ||
SENSIMED | $18M | 09 Oct 2012 | Lausanne, Vaud, Switzerland | ||
Anergis | $20M | 28 Mar 2011 | Vaud, Switzerland | ||
Evolva | $17M | 11 Dec 2009 | Aargau, Switzerland | ||
Evolva | $30M | 22 Oct 2009 | Aargau, Switzerland | ||
Symetis | $21M | 01 Jul 2009 | Vaud, Switzerland | ||
SENSIMED | $8M | 17 Dec 2007 | Lausanne, Vaud, Switzerland | ||
Addex Therapeutics | $38M | 17 May 2004 | Geneva, Switzerland | ||
immatics biotechnologies | $9M | 11 Feb 2004 | Baden-Württemberg |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Anergis | $8M | 07 Feb 2014 | Vaud, Switzerland | ||
SENSIMED | $18M | 09 Oct 2012 | Lausanne, Vaud, Switzerland | ||
Anergis | $20M | 28 Mar 2011 | Vaud, Switzerland | ||
Evolva | $17M | 11 Dec 2009 | Aargau, Switzerland | ||
Evolva | $30M | 22 Oct 2009 | Aargau, Switzerland | ||
Symetis | $21M | 01 Jul 2009 | Vaud, Switzerland | ||
SENSIMED | $8M | 17 Dec 2007 | Lausanne, Vaud, Switzerland | ||
Addex Therapeutics | $38M | 17 May 2004 | Geneva, Switzerland | ||
immatics biotechnologies | $9M | 11 Feb 2004 | Baden-Württemberg |
